Off-label drug use in paediatrics: A World-Wide problem

Current Drug Targets

Volumn 13, Issue 7, 2012, Pages 878-884

  Lenk, Christian ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Ethical and legal regulation; Off label use; Paediatrics

Indexed keywords

ZIPRASIDONE;

ARTICLE; DEVELOPING COUNTRY; DRUG LEGISLATION; EUROPEAN UNION; EXPLOSIVE PERSONALITY DISORDER; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; NONHUMAN; OFF LABEL DRUG USE; PEDIATRICS; PERSONALITY DISORDER; PSYCHOSIS; RISK ASSESSMENT; TREATMENT INDICATION; UNITED STATES;

EID: 84861707955     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800675759     Document Type: Article

References (16)

1. Hoppu K. Paediatric clinical pharmacology-at the beginning of a new era. Eur J Clin Pharmacol 2008; 64: 201-5.
2. Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin Pharmacol Ther 2007; 81: 477-9.
3. Koch Ph. Off-label use in der Kinderheilkunde. Die medizinethische Bewertung der zulassungsüberschreitenden Arzneimitteltherapie unter Berücksichtigung der Meinung der Eltern. [Off-Label Use in Paediatrics. The Ethical Assessment of Off-Label Therapy in Consideration of the Parents' Opinion.] Dissertation, University of Göttingen, Göttingen 2008.
4. Council of Europe. Council Resolution of 14 Dec 2000 on Paediatric Medicinal Products. (2001/C 17/01) Official Journal of the European Communities, 19.1.2001.
5. European Commission. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) no 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union, 27.12.2006.
6. Ceci A, Felisi M, Baiardi P, et al. Medicines for Children licensed by the European Medicines Agency (EMEA): The Balance after 10 Years. Eur J Clin Pharmacol 2006; 16: 947-52.
7. Zheng Z, Xu F. Chinese pharmacists propose patient consent for unlabeled use of medications. J Managed Care Pharm 2010; 16: 640.
8. Lenk C, Koch P, Zappel H, et al. Off-label, off-limits? parental awareness and attitudes towards off-label use in paediatrics. Eur J Pediatr 2009; 168: 1473-8.
9. Surabhi SJ, Bavedekar SB, Gogtay NJ, et al. Off-label drug use in children. Ind J Pediatr 2008; 75: 1133-6.
10. Council of Europe. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. Oviedo, 4.4.1997; conventions. coe. int/Treaty/en/ Treaties/html/164. htm (accessed on 20.5.2011).
11. EU Ad Hoc Group (for the Development of Implementing Guidelines for Directive 2001/20/EC), Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Paediatric Population. Brussels 2008. ftp.cordis.europa.eu/pub/fp7/docs/ethicalconsiderations-paediatrics_en.pdf (accessed on 20.5.2011).
12. Penfold RB, Kelleher KJ, Wang W, et al. Pediatric uptake of a newly available antipsychotic medication. Pediatrics 2010; 125: 475-82.
13. Elbe D, Carandang CG. Focus on Ziprasidone: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2008; 17: 220-9.
14. Rocchi F, Paolucci P, Ceci A, et al. The European Paediatric Legislation: benefits and perspectives. Ital J Pediatr 2010; 36: 56.
15. Albrecht H. "Blockiertes Register. " [Blocked registry.] Die Zeit, 22.4.2004; www.zeit.de/2004/18/M-Studien-Register (accessed on 30.5.2011).
16. Chalumeau M, Tréluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child2000; 83: 502-5.